Chris Klaus
Angel Investor
Atlanta, United States
Chris Klaus is a seed investor in Atlanta focused on Health Care and Software. Chris Klaus was the founder and CTO of Internet Security Systems (ISS), which was acquired by IBM for $1.3B. Chris formed ISS in the early 1990s as a student at the Georgia Institute of Technology. He grew the company to 1,200 employees and took the company public. He is currently founder and CEO of Kaneva, the first company to integrate socialnetworking, shared media, games and collaborative communities into an immersive 3D virtual world.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Chris Klaus invests in
Stages Chris Klaus invests in
Countries Chris Klaus invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 4 (40%)
- Software 3 (30%)
- Machine Learning 3 (30%)
- SaaS 2 (20%)
- Artificial Intelligence 2 (20%)
Stage
- Seed 6 (60%)
- Pre-Seed 3 (30%)
- Series A 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Tabnam is an AI-powered product research tool that scrapes the internet for customer experience data about a product to help shoppers make more informed decisions. | Pre-Seed / Mar 29, 2022 | ||
| Industrial IoT Data Pipeline for Artificial Intelligence | $710K / Pre-Seed / Feb 10, 2022 | ||
| SlateSafety provides real-time physiological monitoring platform that alerts on overexertion and heat stress. | $1.7M / Seed / Jan 28, 2022 | ||
| Reframe is the leading app to help people cut back on drinking alcohol. | $12.5M / Series A / Jan 18, 2022 | ||
| Reframe is the leading app to help people cut back on drinking alcohol. | $1.4M / Seed / Mar 08, 2021 | ||
| Real time monitoring of machine learning systems. | $900K / Seed / Nov 10, 2020 | ||
| Insight Optics, is an impact driven startup dedicated to connecting Primary Care Providers with local specialists for assisted diagnostics. We do the heavy lifting with machine learning and computer vision to ensure untrained individuals have captured the right content and that it is of a diagnosable quality prior to transmission. We have built oursolution to ensure that we can capture non-adherent patients where they already are by deskilling the process and improving accessibility for the most rural, impoverished, and marginalized populations.Business Overview: Insight Optics empowers primary care providers (PCPs) to record and refer preventative pre-screening videos to local specialists for assisted diagnostics. Our goal is to enable PCPs to efficiently detect early signs of preventable diseases before permanent damage is done. We accomplish this by providing PCPs a platform to connect and send patient data to local specialists. This allows both users to monetize otherwise unrealized referral incentives and provide better care.Problem: Over 154 million patients in the United States are recommended for an annual retinal exam, especially those with a history of diabetes or high blood pressure. Unfortunately, less than 50% of this population will receive their screening due to the difficulty of visiting a specialist, lack of education or available specialists. However, most of these patients do see PCPs annually. Solution: We’ve developed a telemedicine PaaS, enabling PCPs to record and refer retinal exams to local specialists for assisted review. PCPs create a new revenue stream through reimbursements and government incentives. Specialists find qualified leads and increase their screening capacity without the need for in-person appointments in a non-adherent population.Benefits: The OptoView system acts as a new revenue stream for both PCPs and specialists through reimbursement. The tool satisfies HEDIS requirements for PCPs and acts as a lead generation tool for specialists to find new patients. Annual reports determine whether managed care organizations receive reimbursements or penalties from state and federal agencies. Our application is designed to satisfy the requirements for annual diabetic eye screenings, increasing an organization’s compliance rates and ophthalmologists prioritize sick patients. | $150K / Pre-Seed / Jul 31, 2019 | ||
| Stord is on a mission to migrate supply chains to the cloud—empowering brands to build sophisticated, agile, and integrated supply chains.Founded in 2015 and headquartered in the heart of Atlanta's vibrant tech community, Stord is pioneering the world's first Cloud Supply Chain. The Cloud Supply Chain is the convergence of the digitaland physical elements of logistics. With Stord's Cloud Supply Chain, businesses can build, expand, and optimize their physical supply chain operations across freight, warehousing, and fulfillment, with the speed, flexibility, and ease of modern cloud software. With a single integration, businesses achieve end-to-end visibility into their whole supply chains from a single dashboard and gain access to Stord's network of hundreds of warehouses, fulfillment centers, and carriers.They are a rapidly growing team that is backed by over $125M from leading investors such as Kleiner Perkins, Founders Fund, BOND, D1 Capital, and more (investors in Amazon, Google, Twitter, and more). They've received awards and recognition from TechCrunch, the Wall Street Journal, VentureBeat, Fortune, Forbes, Inc., TAG, Atlanta Business Chronicle, and more.The future of supply chains is in the cloud. Come help us help businesses out-deliver their competition with the Cloud Supply Chain. | $2.6M / Seed / Apr 18, 2018 | ||
| QMENTA is a cloud-native medical imaging AI platform for regulated clinical trials and research. The platform manages the full imaging workflow — from multi-site data ingestion and real-time QC through AI analysis, central review, and regulatory submission — in one FDA 21 CFR Part 11, HIPAA, GDPR, and ISO 13485 compliant system. QMENTA is510(k)-cleared, vendor-neutral across all major scanner manufacturers, and deployable on GCP, AWS, or Azure. The platform is in production across more than 400 imaging sites with over 16 million imaging files processed. | $3.2M / Seed / May 05, 2017 | ||
| Intellimedix develops innovative approaches to accelerate the discovery and development of new treatments for known human diseases. The company, headquartered in Atlanta, GA with a research laboratory in Cambridge, MA, is guided by the principle of open innovation. Intellimedix works closely with patients and their doctors, non-profits, andacademic institutions in order to promote the free flow of knowledge and information for the benefit of all. Intellimedix has teamed up with world-class experts in the fields of systems biology, computer science, neuroscience, and biological engineering. | $2.3M / Seed / Feb 23, 2015 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Chris Klaus invest in?
Chris Klaus invests primarily in Health Care, Software and Machine Learning startups, most often at Seed and Pre-Seed stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Chris Klaus?
Public channels for Chris Klaus include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Chris Klaus last invest?
The most recent investment recorded for Chris Klaus closed in Mar 2022. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
